6922 — Cryofocus Medtech Shanghai Co Income Statement
0.000.00%
- HK$1.92bn
- HK$1.83bn
- CNY40.95m
Annual income statement for Cryofocus Medtech Shanghai Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 9.05 | 22.4 | 27.1 | 41 |
Cost of Revenue | ||||
Gross Profit | 4.64 | 15.5 | 19.4 | 31.1 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 168 | 149 | 145 | 146 |
Operating Profit | -159 | -126 | -118 | -105 |
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -159 | -126 | -118 | -106 |
Provision for Income Taxes | ||||
Net Income After Taxes | -159 | -126 | -118 | -106 |
Minority Interest | ||||
Net Income Before Extraordinary Items | ||||
Net Income | -137 | -102 | -112 | -97.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -137 | -102 | -112 | -97.5 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.573 | -0.374 | -0.582 | -0.408 |